In addition to predicting survival risk, our study is helpful for dynamically monitoring the anti-tumor function of CD8+TILs in patients based on their exhaustion status in AITL and can provide suggestions for developing individualized therapeutic approaches. This evidence concerns the gene CD8A and angioimmunoblastic T-cell lymphoma.